Drug treatment options for the 2019-new coronavirus (2019-nCoV)
- PMID: 31996494
- DOI: 10.5582/bst.2020.01020
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Abstract
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.
Keywords: 2019-nCoV; Coronaviruses; pneumonia.
Similar articles
-
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949. In Vivo. 2020. PMID: 32503817 Free PMC article. Review.
-
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00399-20. doi: 10.1128/AAC.00399-20. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32152082 Free PMC article. Review.
-
[Potential antiviral therapeutics for 2019 Novel Coronavirus].Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32164080 Chinese.
-
Treatment options for COVID-19: The reality and challenges.J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4. J Microbiol Immunol Infect. 2020. PMID: 32307245 Free PMC article. Review.
-
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13. J Infect Public Health. 2020. PMID: 32684351 Free PMC article.
Cited by
-
Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.Aust N Z J Public Health. 2020 Dec;44(6):437-439. doi: 10.1111/1753-6405.13044. Epub 2020 Oct 12. Aust N Z J Public Health. 2020. PMID: 33044799 Free PMC article. Review. No abstract available.
-
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.Cell Transplant. 2021 Jan-Dec;30:963689721995455. doi: 10.1177/0963689721995455. Cell Transplant. 2021. PMID: 33650894 Free PMC article. Review.
-
Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.Front Immunol. 2021 Mar 26;12:655528. doi: 10.3389/fimmu.2021.655528. eCollection 2021. Front Immunol. 2021. PMID: 33841439 Free PMC article. Review.
-
Covid-19 pandemic outburst in Saudi Arabia: A glimpse.Saudi J Biol Sci. 2020 Dec;27(12):3547-3552. doi: 10.1016/j.sjbs.2020.07.026. Epub 2020 Jul 30. Saudi J Biol Sci. 2020. PMID: 32837220 Free PMC article. Review.
-
Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review.Biologia (Bratisl). 2021;76(9):2655-2673. doi: 10.1007/s11756-021-00792-z. Epub 2021 Jun 2. Biologia (Bratisl). 2021. PMID: 34092799 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials